Summary
68 / 100 · Bulios Score
What speaks for it
- Revenue grew by 23% a year over the last 3 years.
- It holds more cash than debt: $4.70M against $872.0K.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 22.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 23% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 40 USD
- Research and development 7.0 USD
- Sales and administration 45 USD
- Taxes and other -0.5 USD
- Net profit 8.4 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 8.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $4 is 13% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Royalty and Other Revenues 51%
- Service 47%
- Other Revenue 2.2%
By region
The company reports no revenue by region.
Royalty and Other Revenues brings in 51% of revenue.
Segments in detail